human clinical trial successful

Not one trade - how times have changed.

Sydney - Thursday - December 7: (RWE Australian Business News) -
OBJ Ltd (ASX code: OBJ) today announced the successful completion of the
second phase of the company's human clinical trial into the enhanced
transdermal delivery of the local anaesthetic Ametop, which uses
Tetracaine as its active ingredient.
The combined results of this study and the earlier April study
show that Dermaportation was able to induce numbness in volunteer
subjects within 20 minutes using one-fifth of the recommended drug
dosage. This represents a significant reduction in both the amount of
drug required and the time to onset compared with manufacturer's
recommended times of 30 to 45 minutes.
At 20 minutes after drug administration, there were
statistically significant differences in the touch-sensitivity between
active and placebo treatment areas in volunteers.
This provides evidence of successful enhanced skin penetration
of tetracaine under the influence of Dermaportation.
A single volunteer study was run in parallel, using 15-minute
Dermaportation and drug contact time, which produced greater numbness
than the control. This suggests that the Dermaportation technology may
be effective in even less time than used in the study.